Motif Bio Share Discussion Threads

[scottdavid70] 25/2/2021 04:25

What happened then? He still wants a BONUS even after all this never materialised?

[scottdavid70] 25/2/2021 04:24

Remember those partners Lumsden was so confident about after the FDA meeting? “ Graham Lumsden, chief executive of Motif Bio (LON:MTFB), tells Proactive Investors he is confident about the path forward for Iclaprim. After a 'collaborative meeting' with the FDA, the American regulator gave the biopharmaceutical company the green light to begin phase 111 clinical trials on its next-generation antibiotic. Lumsden is now putting together a strategic business development plan looking at appropriate partners for one or both of the clinical trials to bring in upfront payments and satisfy funding requirements for the trials.”

[scottdavid70] 25/2/2021 00:39

£100,000 is huge for a cash shell and he shouldn’t be paid it unless there is SIGNIFICANT upside in a sale of Iclaprim before the RTO We need to stop the greed

[scottdavid70] 25/2/2021 00:37

Remember this man is going to take over £100,000 BONUS for failing to achieve that goal and many others but getting the BONUS for something he created by not selling or getting any value for investors with Iclaprim- his only job. Are you happy to see him trouser another six figure amount for failing?

[scottdavid70] 25/2/2021 00:35

Remember when the company said the USA was ALWAYS the focus for approval for Iclaprim? Well in 2015 and even up to 2018 that wasn’t the case but strangely the EMA got pulled silently. This is from 2015 where they were very much heralding the importance of European approval of the REVIVE trials “ Graham Lumsden, chief executive of Motif Bio (LON:MTFB), says the company’s latest agreement with EU regulators paves the way for its antibiotic, Iclaprim, to be licenced in Europe. This week the firm received written scientific advice from the Medicines Evaluation Board (MEB) in the Netherlands stating its phase-III studies on the treatment, plus microbiological data, should be filed for scrutiny. The advice confirms that Motif’s two upcoming Phase III clinical trials on iclaprim—for the treatment of skin infections—are acceptable as pivotal registration studies for approval in the European Union.”

[scottdavid70] 21/2/2021 13:27

Strange it was delayed and then not approved yet we as shareholders weren’t aware of any liver issues but there were 2 experts on standby for the AdComm and then not a small trial or labelling after FDA meeting Type A but full blown phase iii trials.... Oh and then after the Type B meeting they announced before the FDA decision what it was but funnily enough before the announcement of the Type A meeting Lumsden was on ProActive saying he couldn’t weight a horse as to which of the 3 potential outcomes it could possibly be. That’s when the AGM was shoved before the official decision so he didn’t have to sit in the room with the investors he was supposed to be acting in the best interests of. Zero reason not to have held the AGM so investors could get answers but he choose not too. So yes I would have definitely done it differently and especially not take full pay for failing for the next 12 months

[bi11y ray va1entine] 20/2/2021 21:02

So what you're saying is Scott, if you had been in charge you would have explained why the NDA submission was delayed just like Lumsden did. And that would've been totally unacceptable.

[scottdavid70] 20/2/2021 21:01

I see Glaxo (GSX) have put 140 million into the AMR Fund. If Iclaprim has a chance of being sold that is the route that is it’s best bet. If it doesn’t get sold the whole thing was a hoax. The cost of buying it vs the research done is a no brainier in terms of what the AMR Fund want to achieve- the outcome will say a lot about what we were actually invested in...

[scottdavid70] 20/2/2021 20:59

First time project vs something that’s been done thousands of times - there was no reason for a delay unless the liver issue was suddenly realised then. Many of us invested here feel that’s when the issue first surfaced- the following actions - cancelled HABP and European submission stopped suggest this. Plus they did countless conferences and not once did the data presented move the share price. If the data was so compelling why didn’t anyone buy in? Something strange in the neighbourhood!!!

[small crow] 20/2/2021 20:07

Scott, I have one 'word' for you - HS2.

[scottdavid70] 20/2/2021 10:49

When you are getting paid $500,000 a year to get it right. Totally unacceptable

[bi11y ray va1entine] 20/2/2021 10:37

He explained in several interviews that the submission process just took longer than expected. When has a big project ever come in on time and on budget?

[bi11y ray va1entine] 20/2/2021 10:35

In the August 15th 2018 Proactive interview he says the NDA submission is hundreds of thousands of pages in length. It's at 1 minute 40 seconds if you want to see for yourself. That's probably an exaggeration though, because the NIH website says they actually run up to 100,000 pages.

[scottdavid70] 19/2/2021 20:40

Because he never fully explained himself - typical of what we have had to deal with He said the NDA was late because it was a 2,000 page submission. Assume he knew that when starting Motif to get Iclaprim approved. This couldn’t have come as a shock. Lame excuse European submission was batted away with “the focus has always been on getting Iclaprim approved in America” . Begs the question why start and waste the money to try to get European approval if that was never the priority. As it came with cancelling the HABP trials. I think 2+2=4 in this case clearly HABP cancellation was never explained fully. Was left in the hazy not worth the money but just another excuse blatantly now. Quality company and superbly run as you can see pre and post FDA decision but we can only see that now with the benefit of hindsight. Lunsden however, despite this, picks up a nice new job and fat salary. 8th wonder of the world

[small crow] 19/2/2021 13:45

What would happen if an RTO was to take place to those with shares?" You might make a great deal of money. Then again, you might not. It all depends on the details, not surprisingly.

[small crow] 19/2/2021 13:34

Not really an explanation that Scott!

[scottdavid70] 19/2/2021 13:26

Because Lumsden wanted his “one shot goal” he missed but didn’t explain why he delayed the shot and then missed an Open goal

[bi11y ray va1entine] 19/2/2021 12:53

Why was the NDA submitted late then? I've looked but can't find any reference to it anywhere.

[scottdavid70] 19/2/2021 08:26

Be honest as to why the NDA submission was late, explain why the HARB trails were stopped and European submission halted. There was clearly something they knew to halt two very pivotal things in Motifs pipeline. Why did you have 2 liver experts on standby if you had no idea that liver toxicity could be an issue? Front up at the AGM post FDA decision after the Type A meeting rather than hiding behind office furniture and still asking for more in salaries that your shareholders had to rebuke. Imagine after failing to have zero conscience to do that? Could have had a chance to explain why the liver experts were on standby at the AGM if he had held it at the same time as they did the year previously. Don’t then sit on a full salary eating up the money so you end you diluting even faster the very people you have asked to invest and then failed to deliver your promise too. There is more but that’s for starters and shows what type of person the former CEO is and was.

[bi11y ray va1entine] 19/2/2021 08:02

Since you're the expert Scott, what would you have done differently if you'd been in charge leading up to the FDA response?

[scottdavid70] 18/2/2021 22:35

Remember Lumsden is up for a BONUS on top of all the money he has taken from you - diluted your shareholding’s - and that Bonus is directly related to a RTO that he caused by not getting Iclaprim approved- not as it should be on a sale or something beneficial for investors who have lost 90% of their INVESTMENT HERE

[scottdavid70] 18/2/2021 22:33

I see the LSE brain trust wonders when updates are coming. Read the RNS not till end of March - until then keep reading about how this company was led and how much of your money has been moved into Directors accounts in salaries despite failing to get Iclaprim approved or sold more recently

[scottdavid70] 18/2/2021 22:32

During all that time Lumsden, despite not getting iclaprim approved took full pay

[scottdavid70] 18/2/2021 22:30

Absolutely not - they had 2 liver experts on standby for the AdComm meeting but we didn’t know that. They cancelled HARP Trials and European Submission for Iclaprim but slotted into a presentation without telling us. They told us no clinical trials were needed in a webcast after the FDA decision but actually we needed full phase iii trials Definitely didn’t lose my money ‘through’; my own fault and the world will hear